Johnson & Johnson (NYSE:JNJ) Price Target Raised to $193.00 at Sanford C. Bernstein

Key Points

• Sanford C. Bernstein increased Johnson & Johnson's price target from $172.00 to $193.00, indicating a potential upside of 2.38% from its previous close.
• Johnson & Johnson reported a quarterly earnings per share (EPS) of $2.77, surpassing estimates, with revenue of $23.74 billion this quarter—a year-over-year increase of 5.8%.
• The company currently has a consensus rating of Moderate Buy from analysts, with a mixed range of ratings including two Strong Buy, eleven Buy, and nine Hold ratings.

Johnson & Johnson (NYSE:JNJ - Get Free Report) had its target price boosted by Sanford C. Bernstein from $172.00 to $193.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a "market perform" rating on the stock. Sanford C. Bernstein's price target indicates a potential upside of 2.38% from the company's previous close.

JNJ has been the subject of a number of other research reports. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Bank of America upped their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the stock a "neutral" rating in a report on Friday. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday, September 16th. Finally, UBS Group set a $198.00 price objective on Johnson & Johnson in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $189.12.

Johnson & Johnson Trading Up 1.4%

Johnson & Johnson stock opened at $188.51 on Monday. The business has a 50-day simple moving average of $176.18 and a two-hundred day simple moving average of $162.83. The company has a market cap of $453.98 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $189.78. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson during the second quarter valued at approximately $27,000. Semmax Financial Advisors Inc. grew its holdings in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $35,000. Highline Wealth Partners LLC grew its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the period. Finally, Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $47,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.